Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Current Leases: 2021-2025

Historic Current Leases for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to $583,000.

  • ARS Pharmaceuticals' Current Leases rose 471.57% to $583,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $583,000, marking a year-over-year increase of 471.57%. This contributed to the annual value of $42,000 for FY2024, which is 82.28% down from last year.
  • Latest data reveals that ARS Pharmaceuticals reported Current Leases of $583,000 as of Q3 2025, which was down 1.02% from $589,000 recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Current Leases ranged from a high of $1.1 million in Q1 2022 and a low of $42,000 during Q4 2024.
  • Over the past 3 years, ARS Pharmaceuticals' median Current Leases value was $232,000 (recorded in 2023), while the average stood at $245,727.
  • As far as peak fluctuations go, ARS Pharmaceuticals' Current Leases tumbled by 82.28% in 2024, and later soared by 471.57% in 2025.
  • ARS Pharmaceuticals' Current Leases (Quarterly) stood at $144,000 in 2021, then soared by 59.72% to $230,000 in 2022, then grew by 3.04% to $237,000 in 2023, then crashed by 82.28% to $42,000 in 2024, then soared by 471.57% to $583,000 in 2025.
  • Its last three reported values are $583,000 in Q3 2025, $589,000 for Q2 2025, and $73,000 during Q1 2025.